Your browser is no longer supported. Please, upgrade your browser.
PRVB Provention Bio, Inc. monthly Stock Chart
Provention Bio, Inc.
Index- P/E- EPS (ttm)-1.05 Insider Own4.70% Shs Outstand47.70M Perf Week17.71%
Market Cap649.78M Forward P/E- EPS next Y-1.71 Insider Trans0.67% Shs Float41.76M Perf Month-11.95%
Income-44.90M PEG- EPS next Q-0.37 Inst Own23.60% Short Float11.57% Perf Quarter-11.18%
Sales- P/S- EPS this Y-34.50% Inst Trans8.12% Short Ratio4.48 Perf Half Y-16.97%
Book/sh1.49 P/B8.21 EPS next Y-25.70% ROA-59.30% Target Price- Perf Year36.80%
Cash/sh1.44 P/C8.48 EPS next 5Y- ROE-63.60% 52W Range4.72 - 18.50 Perf YTD-17.92%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-33.89% Beta-
Dividend %- Quick Ratio11.30 Sales past 5Y- Gross Margin- 52W Low159.11% ATR0.88
Employees19 Current Ratio11.30 Sales Q/Q- Oper. Margin- RSI (14)51.87 Volatility9.98% 7.33%
OptionableYes Debt/Eq0.00 EPS Q/Q10.20% Profit Margin- Rel Volume0.73 Prev Close11.80
ShortableYes LT Debt/Eq0.00 EarningsAug 06 AMC Payout- Avg Volume1.08M Price12.23
Recom1.70 SMA205.89% SMA50-8.32% SMA2002.60% Volume783,549 Change3.64%
Jun-16-20Reiterated H.C. Wainwright Buy $20 → $26
Jun-04-20Initiated RBC Capital Mkts Outperform $25
Jun-04-20Initiated Oppenheimer Outperform $29
Jan-24-20Initiated Cantor Fitzgerald Overweight $25
Jun-26-19Reiterated H.C. Wainwright Buy $8 → $20
Jun-10-19Initiated Chardan Capital Markets Buy $20
Feb-22-19Initiated SVB Leerink Outperform $6
Aug-06-20 07:00AM  
Aug-03-20 04:05PM  
Jul-30-20 07:00AM  
Jul-02-20 09:15AM  
Jun-30-20 04:30PM  
Jun-29-20 07:00AM  
Jun-22-20 04:01PM  
Jun-19-20 10:26AM  
Jun-17-20 10:16PM  
Jun-16-20 04:01PM  
Jun-15-20 05:02PM  
May-28-20 07:00AM  
May-20-20 07:00AM  
May-18-20 07:00AM  
May-08-20 07:30PM  
Apr-30-20 07:00AM  
Apr-16-20 07:00AM  
Apr-01-20 09:09AM  
Mar-21-20 08:54AM  
Mar-17-20 08:48AM  
Mar-16-20 04:05PM  
Mar-12-20 07:05AM  
Mar-05-20 07:00AM  
Feb-19-20 07:00AM  
Feb-05-20 12:41PM  
Jan-23-20 06:30AM  
Jan-08-20 07:00AM  
Dec-30-19 02:44PM  
Dec-17-19 05:19PM  
Dec-12-19 07:00AM  
Dec-05-19 06:15AM  
Dec-04-19 12:00PM  
Nov-21-19 07:32AM  
Nov-05-19 04:05PM  
Oct-29-19 12:52PM  
Oct-24-19 07:00AM  
Oct-22-19 07:00AM  
Sep-26-19 07:00AM  
Sep-25-19 07:00AM  
Sep-24-19 07:00AM  
Sep-19-19 07:39AM  
Sep-18-19 08:26PM  
Aug-27-19 03:30PM  
Aug-20-19 07:00AM  
Aug-09-19 08:15AM  
Aug-08-19 07:00AM  
Aug-06-19 07:00AM  
Aug-05-19 12:21PM  
Jul-12-19 07:15AM  
Jul-01-19 07:30AM  
Jun-14-19 12:31PM  
Jun-13-19 07:49AM  
Jun-12-19 08:44AM  
Jun-11-19 09:43AM  
Jun-10-19 05:32PM  
Jun-09-19 01:05PM  
May-27-19 11:02AM  
May-09-19 07:56AM  
May-08-19 04:30PM  
Apr-24-19 07:00AM  
Apr-12-19 09:49AM  
Apr-09-19 07:00AM  
Apr-02-19 07:00AM  
Mar-28-19 07:00AM  
Mar-19-19 04:05PM  
Mar-12-19 04:05PM  
Feb-13-19 07:33AM  
Jan-28-19 07:33AM  
Jan-03-19 07:33AM  
Dec-25-18 10:46AM  
Nov-28-18 07:33AM  
Nov-08-18 07:33AM  
Nov-05-18 09:00AM  
Oct-23-18 07:33AM  
Sep-11-18 07:33AM  
Sep-05-18 07:33AM  
Aug-13-18 08:00AM  
Jul-31-18 07:33AM  
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, an oral CSF-1R inhibitor, which is in Phase IIa clinical trial for the treatment of Crohn's disease; PRV-3279, which has completed Phase 1b clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease. Provention Bio, Inc. was incorporated in 2016 and is based in Oldwick, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Leon FranciscoChief Scientific OfficerJun 24Buy15.432,00030,8622,565,450Jun 24 04:22 PM
Bluestone JeffreyDirectorApr 10Option Exercise2.3632,24676,10139,571Apr 14 05:00 PM
Leon FranciscoChief Scientific OfficerMar 19Buy5.9210,00059,2002,563,450Mar 20 06:15 AM
Hoitt JasonChief Commercial OfficerMar 19Buy5.434,50024,4354,500Mar 20 06:15 AM
Ramos EleanorCMO & COODec 26Buy14.342,00028,68062,000Dec 26 05:00 PM
Palmer AshleighPresident and CEODec 20Buy11.392,07523,6342,563,000Dec 23 04:30 PM
Leon FranciscoChief Scientific OfficerDec 16Buy11.922,00023,8402,553,450Dec 16 05:00 PM